US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma
Keith A Betts, Per-Olof Thuresson, Federico Felizzi, Ella X Du, Ibou Dieye, Jia Li, Mathias Schulz, Anthony S Masaquel, Keith A Betts, Per-Olof Thuresson, Federico Felizzi, Ella X Du, Ibou Dieye, Jia Li, Mathias Schulz, Anthony S Masaquel
Abstract
Aim: To evaluate the cost-effectiveness of polatuzumab vedotin (pola) + bendamustine + rituximab (BR) in relapsed/refractory diffuse large B-cell lymphoma based on the GO29365 trial from a US payer's perspective. Materials & methods: A partitioned survival model used progression-free survival and overall survival data from the GO29365 trial. The base case analysis assumed overall survival was informed by progression-free survival; a mixture cure model estimated proportion of long-term survivors. Results: In the base case, pola + BR was cost-effective versus BR at US$35,864 per quality-adjusted life year gained. Probabilistic and one-way sensitivity analyses showed that the findings were robust. Conclusion: Pola + BR is cost-effective versus BR for the treatment of transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma in the US.
Trial registration: ClinicalTrials.gov NCT02257567.
Keywords: DLBCL; bendamustine; cost–effectiveness; polatuzumab vedotin; relapsed/refractory; rituximab.
Source: PubMed